Clinical trial NCT02904109: Influence of Triflusal on Cognitive Functions in Subjects Under Chronic Stress
Official title: Randomized Placebo Controlled Phase II Cross Over Study on the Influence of Triflusal on Cognitive Functions in Subjects Under Chronic Stress
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Healthy
Lead sponsor: University of Basel
Sponsor class: OTHER
First posted: 2016-09-16
Enrollment: 41
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to investigate the effects of the eNOS activating agent triflusal on episodic memory and cognitive functions in participants under chronic stress.

Detailed description: Randomised, placebo controlled, double blind, cross-over design

Primary study outcome is:

Performance in a verbal memory task.

Main secondary outcomes are: Performance in working memory and cognitive tasks and influence on mood, depression and anxiety and subjective memory impairment.

Once daily oral administration of 600 mg triflusal and placebo mannitol for 8 days in a cross-over trial with a washout period of at least 14 days between the two periods. Each participant will take triflusal as well as placebo

Eligibility criteria: Inclusion Criteria:

* male or female
* normotensive (BP between 90/60mmHg and 140/90mmHg)
* BMI between 19 and 29 kg/m2
* aged between 18 and 40 years
* experiencing chronic stress for at least 1 month (TICS sum score in subscale "overextension at work" \>= 55)
* native or fluent German-speaking
* able and willing to give written informed consent as documented by signature and comply with the requirements of the study protocol
* willing to donate saliva sample for DNA-analysis
* female: willing to perform a pregnancy test at the beginning of both medication phase and at the follow-up visit.

Exclusion Criteria:

* Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to salicylates and other NSAIDs
* acute or chronic psychiatric disorder (e.g. major depression, psychoses, somatoform disorder, suicidal tendency) except symptoms of chronic stress
* cognitive impairment as detected by DemTect
* concomitant acute or chronic disease state (e.g. renal failure, hepatic dysfunction, cardiovascular disease, acute infections etc.)
* women who are pregnant or breast feeding
* intention to become pregnant during the course of the study
* lack of safe contraception, defined as: female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases
* active peptic ulcer or antecedents or complicated peptic ulcer or history of peptic ulcer. Any other active pathological bleeding
* history of coagulation abnormality
* thyroid problems
* laboratory exclusion criteria: clinically significant values of blood count (incl. platelets), coagulation status or blood chemistry outside reference range of laboratory
* pathological ECG
* known or suspected non-compliance, drug or alcohol abuse
* inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
* participation in another study with investigational drug within the 30 days preceding -

Primary outcomes:
measure: Change in performance in episodic memory task as assessed by a verbal memory task between placebo and verum at two different time points. Verbal task as described in ( de Quervain, Henke et al. 2003). Number of correctly *
timeFrame: Timepoint 1:45 minutes after first medication. Timepoint 1:45 minutes after last medication.
Secondary outcomes:
measure: Change in performance in working memory task between placebo and verum at two different time points.
timeFrame: Timepoint 1:45 minutes after first medication. Timepoint 1:45 minutes after last medication.
measure: Change in performance in episodic memory task between placebo and verum at two different time points.
timeFrame: Timepoint 1:45 minutes after first medication. Timepoint 1:45 minutes after last medication.
measure: Change in performance in a memory game between placebo and verum at two different time points.
timeFrame: Timepoint 1:45 minutes after first medication. Timepoint 1:45 minutes after last medication.
measure: Change in subjective memory impairment between placebo and verum
timeFrame: 20 min before last medication of each placebo and verum
measure: Mood state changes between placebo and verum at two different time points.
timeFrame: Timepoint 1:45 minutes after first medication. Timepoint 1:45 minutes after last medication.
measure: Changes in depressive symptoms between placebo and verum at two different time points.
timeFrame: Timepoint 1:45 minutes after first medication. Timepoint 1:45 minutes after last medication.
measure: Changes in anxiety symptoms between placebo and verum at two different time points.
timeFrame: Timepoint 1:45 minutes after first medication. Timepoint 1:45 minutes after last medication.
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: University of Basel, Division of Cognitive Neuroscience
Study officials:
References: